摘要:
In certain aspects the invention provides HIV-1 engineered envelope proteins and their uses. The engineered envelopes comprise a sequence that prevents cleavage of the envelope associated with recombinant expression in a cell line, and N-terminal deletion which improves envelope expression as a monomer.
摘要:
In certain aspects the invention provides immonogenic compositions comprising CH848 HIV-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.
摘要:
The present invention relates, in general, to human B cells, and, in particular to a method of immortalizing and cloning human B cells and to monoclonal antibodies derived therefrom. The invention further relates to methods of using the monoclonal antibodies for therapeutic and diagnostic purposes.
摘要:
The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.
摘要:
In certain aspects the invention provides a selection of HIV- 1 envelopes suitable for use as immunogens, and methods of using these immunogens in vaccination to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize. In other embodiments, the immunogens and methods of using these comprise an immune modulating component.